DTE
49
-5
CRM
44
2
PCG
77
5
IR
71
-3
NWSA
60
2
CNP
54
2
NEE
42
4
SLB
45
-3
NTRS
34
2
PLD
40
-5
JBHT
56
27
HAL
50
-3
ADSK
45
-5
DOW
43
-4
RCL
58
3
KHC
47
4
AVGO
42
-5
PFG
55
15
URI
50
-6
HUM
45
2
DTE
49
-5
CRM
44
2
PCG
77
5
IR
71
-3
NWSA
60
2
CNP
54
2
NEE
42
4
SLB
45
-3
NTRS
34
2
PLD
40
-5
JBHT
56
27
HAL
50
-3
ADSK
45
-5
DOW
43
-4
RCL
58
3
KHC
47
4
AVGO
42
-5
PFG
55
15
URI
50
-6
HUM
45
2
Financhill
Back

Protalix BioTherapeutics 10K Form

Sell
40

PLX
Protalix BioTherapeutics

Last Price:
1.13
Seasonality Move:
3.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $65.49M
Cash Flow: $3.35M
Price / Cash Flow: 0
Annual Sales: $0.46
Price / Book: 2.48

Profitability

EPS (TTM): 0.02000
Net Income (TTM): $8.31M
Gross Margin: $42.51M
Return on Equity: 41.07%
Return on Assets: 10.86%

Protalix BioTherapeutics Earnings Forecast

Key Protalix BioTherapeutics Financial Ratios

  • The Gross Profit Margin over the past 26 years for PLX is 64.91%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.84% of Gross Profit Margin.
  • The Research & Development expenses have been 26.10% of Revenue.
  • The Interest Expense is 38.26% of Operating Income.
  • The Net Earning history of PLX is 12.69% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Protalix BioTherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0.6
Current Ratio: 1.54
Quick Ratio: 1.09

Price-to-Earnings

Trailing P/E Ratio: 12.67
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Sell
40
Protalix BioTherapeutics (PLX) is a Sell

Is Protalix BioTherapeutics a Buy or a Sell?